Dr. Robin Downing podcast spotlights multimodal OA pain care

CURRENT FULL VERSION: Clinician’s Brief is putting osteoarthritis pain management back in focus with a sponsored podcast featuring Dr. Robin Downing, one of the better-known voices in veterinary pain medicine. Hosted by Dr. Beth Molleson and backed by PRN Pharmacal, the episode highlights practical management of pain and inflammation in arthritis patients, with an emphasis on implementing broader pain-control strategies and helping pet parents recognize signs of chronic pain earlier. (cliniciansbrief.com)

That focus fits the larger direction of small animal practice. Osteoarthritis remains one of the most common chronic pain conditions in dogs, and recent guidance from AAHA has pushed the profession toward structured pain assessment, tailored treatment plans, multimodal therapy, and more deliberate client communication. Those guidelines specifically call for combining pharmacologic and nonpharmacologic approaches, regular reevaluation, and team-based management rather than relying on a single intervention. A separate Clinician’s Brief partner podcast, sponsored by Hill’s Pet Nutrition and featuring sports medicine and rehab specialist Dr. Matt Brunke, points in the same direction by framing mobility and joint health as a broader functional issue, not just a medication decision. (aaha.org)

The Downing podcast itself appears aimed at that practical gap: not whether OA pain exists, but how clinicians build more complete plans around it. Clinician’s Brief describes the discussion as covering implementation of “the most complete and effective strategies for pain control” and communication with pet parents to identify pain and improve quality of life. That framing mirrors a broader industry shift toward earlier recognition of mobility change, more formalized OA staging, and proactive management before severe disability sets in. Brunke’s mobility-focused discussion adds another layer: clinicians should think beyond drugs and supplements alone, especially in patients dealing with arthritis, ligament injury, or surgical recovery, where function and activity are central to quality of life. (cliniciansbrief.com)

Brunke also highlights an easy blind spot in joint-health conversations: cats. In the podcast, he notes that cats are often overlooked even though obesity is common and age-related primary osteoarthritis can significantly affect comfort and mobility. That matters because mobility management is not only about the dog that is obviously limping; it also includes the older or overweight cat whose activity has quietly declined. The practical takeaway is consistent with the broader multimodal message running through both podcasts: earlier recognition, weight management, and functional support matter before cases become severe.

Recent research has also expanded the evidence base around newer OA therapeutics. In a randomized, multicenter clinical trial published in Frontiers in Veterinary Science on March 24, 2025, 101 dogs with appendicular OA were assigned to either monthly bedinvetmab or daily meloxicam. Both groups showed significant reductions in Canine Orthopaedic Index scores relative to baseline, and while the bedinvetmab group had a larger mean reduction, the difference was not statistically significant. The study reported four adverse events in the bedinvetmab group versus 17 in the meloxicam group, nine of them gastrointestinal, and more dogs in the bedinvetmab arm completed the study. Zoetis said the findings support existing recommendations that both NSAIDs and Librela can be considered first-line options for canine OA pain. (frontiersin.org)

At the same time, the regulatory picture has become more nuanced. FDA says Librela was approved on May 5, 2023, and later completed an evaluation of adverse events reported in treated dogs. On February 18, 2025, FDA recorded safety-related labeling changes for Librela that added an Information for Dog Owners section instructing veterinarians to discuss the Client Information Sheet before administration, with emphasis on potential adverse drug events and development of an exercise plan for return to activity. FDA also issued a Dear Veterinarian letter on reported adverse events, underscoring the importance of reporting and counseling rather than treating OA injections as low-touch therapy. (fda.gov)

That’s where Downing’s message is likely to resonate most. The profession is balancing more therapeutic choice with more responsibility to guide use carefully. AAHA’s guidance stresses individualized dosing, monitoring for side effects, physical therapy and environmental modification, and open conversations with pet parents about realistic expectations. Brunke’s comments on mobility and rehab reinforce that OA plans should be built around how the patient moves and functions day to day, not just around which analgesic is chosen. Other recent veterinary commentary has similarly emphasized that OA plans should be patient-specific and multimodal, not “cookbook” medicine. (aaha.org)

Why it matters: For veterinary teams, this story is really about clinical process. OA care is becoming more layered: NSAIDs remain foundational for many patients, anti-NGF monoclonal antibodies have added another first-line option for some dogs, and rehab, weight management, nutrition, home modification, and serial reassessment are increasingly part of standard practice. The added mobility-and-joint-health framing from Brunke’s podcast also broadens the conversation beyond classic canine OA to include post-injury recovery, functional decline, and underrecognized feline arthritis. That raises the bar for case selection, monitoring, and pet parent communication. A podcast like this won’t change policy, but it does reflect where the market and the medicine are heading: toward multimodal plans that are easier for pet parents to understand, and harder for clinics to manage casually. (aaha.org)

What to watch: Watch for more education and protocol-building around how clinics sequence NSAIDs, injectable anti-NGF drugs, rehab, nutrition, weight management, and adjunctive options, especially as regulators, manufacturers, and frontline clinicians continue refining safety communication and return-to-activity guidance. Also expect more attention to earlier mobility screening and to patient groups that are easy to miss, especially cats with obesity-related or age-related joint disease. (fda.gov)